vida: extract claims from 2026-05-05-statnews-true-risk-eating-disorders-glp1-april2026

- Source: inbox/queue/2026-05-05-statnews-true-risk-eating-disorders-glp1-april2026.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-eating-disorder-causality-expert-divergence-reflects-evidence-gap.md

@@ -17,3 +17,10 @@ related: ["glp1-eating-disorder-pharmacovigilance-signal-class-effect-obesity-po
 # Expert divergence on GLP-1 eating disorder causality reflects fundamental evidence gap between clinical pattern recognition and epidemiological confirmation
 
 Dr. Aaron Keshen reports EDs developing 'in people who take drugs as prescribed' supporting direct causality, while Dr. Anjali Pandit states 'not seeing this frequently' suggesting prescriber screening matters significantly. This is not a scientific debate about interpretation of shared data — it's a pre-data debate where different clinical populations and practices produce different observed patterns. Keshen's observation supports pharmacological causation; Pandit's suggests population selection (careful screening prevents cases). The divergence itself is evidence of the current state: we are in the clinical pattern recognition phase before systematic epidemiological data. NBC News notes 'no drug label warnings about ED risk currently exist' and the Collaborative of Eating Disorders Organizations is 'calling for mandatory screening before prescribing' — regulatory and professional responses to uncertainty rather than established risk. This represents the characteristic evidence gap where case reports accumulate but incidence rates, risk factors, and causal pathways remain unquantified.
+
+
+## Supporting Evidence
+
+**Source:** STAT News, April 27, 2026
+
+STAT News explicitly characterizes the eating disorder risk evidence base as 'scant' and frames the article around determining 'true risk' - indicating ongoing uncertainty about causality versus population selection effects. The 1.28% incidence figure lacks control group comparison, making causal attribution impossible from this data alone.

domains/health/glp1-eating-disorder-pharmacovigilance-signal-class-effect-obesity-population-specific.md

@@ -45,3 +45,10 @@ Australian DAEN database shows exceptionally high ROR (17.66) for dulaglutide ea
 **Source:** NBC News 2024-08-15
 
 FDA adverse event analysis found 'greater risk of abuse among patients taking semaglutide' compared to other weight-loss drugs (not quantified). Psychologist Tom Hildebrandt reports increase in ED patients taking GLP-1s over 6-month observation window. Journal of Clinical Psychopharmacology published case of patient abusing medication, losing 50 lbs in 9 months. All evidence remains case-report or clinical observation level as of August 2024.
+
+
+## Extending Evidence
+
+**Source:** STAT News, April 27, 2026, ISPOR analysis
+
+ISPOR real-world analysis of 60,000+ GLP-1 users found 1.28% diagnosed with eating disorder within two years. This is total incidence in GLP-1 user population without control group comparison. If 1 in 8 Americans takes a GLP-1, this rate projects to 420,000+ people developing eating disorders. STAT News characterizes the evidence base as 'scant' and quotes expert assessment that 'physicians, trialists, regulators, policymakers, and drug developers are unprepared for this coming wave.'

domains/health/glp1-pre-treatment-eating-disorder-screening-recommended-not-required.md

@@ -45,3 +45,10 @@ ANAD (the authoritative US professional society for eating disorders) formalizes
 **Source:** Northwestern Medicine JCI 2025
 
 The AgRP silencing mechanism strengthens the case for mandatory (not just recommended) pre-treatment screening. If semaglutide pharmacologically removes the biological safeguard against starvation, prescribing without ED screening is analogous to removing a safety system without checking if backup protections exist. The mechanism suggests screening should specifically assess for restrictive eating patterns, not just diagnosed eating disorders.
+
+
+## Extending Evidence
+
+**Source:** STAT News, April 27, 2026
+
+Expert assessment states that 'physicians, trialists, regulators, policymakers, and drug developers are unprepared for this coming wave' of eating disorder cases, suggesting systematic infrastructure gaps beyond individual screening practices. The 420,000-person projection creates urgency for screening infrastructure that current prescribing lacks.

inbox/archive/health/2026-05-05-statnews-true-risk-eating-disorders-glp1-april2026.md

@@ -7,10 +7,13 @@ date: 2026-04-27
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-05
 priority: high
 tags: [glp-1, eating-disorders, semaglutide, incidence, regulatory-gap, screening, evidence-gap, pharmacovigilance]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content